EA200601089A1 - Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение - Google Patents

Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение

Info

Publication number
EA200601089A1
EA200601089A1 EA200601089A EA200601089A EA200601089A1 EA 200601089 A1 EA200601089 A1 EA 200601089A1 EA 200601089 A EA200601089 A EA 200601089A EA 200601089 A EA200601089 A EA 200601089A EA 200601089 A1 EA200601089 A1 EA 200601089A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patch
hormones
need
transdermal delivery
use agents
Prior art date
Application number
EA200601089A
Other languages
English (en)
Other versions
EA011160B1 (ru
Inventor
Штефан Брахт
Михаэль Диттген
Петра Хубер
Томас Ланггут
Дирк Шенк
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of EA200601089A1 publication Critical patent/EA200601089A1/ru
Publication of EA011160B1 publication Critical patent/EA011160B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к пластырю, который включает слой, содержащий лекарственное средство, с низким содержанием гормонов, таких как гестоден, и необязательно эстроген (например, этинилэстрадиол). При использовании пластыря для женщины достигаются уровни концентрации гестодена в плазме крови по крайней мере 1,0 нг/мл при условиях устойчивого состояния, без необходимости введения в слой, содержащий лекарственное средство, агентов, способствующих всасыванию, или агентов, усиливающих проникновение. Удовлетворительные уровни гормонов в плазме крови также достигаются в течение периода по крайней мере 1 неделя, что делает пластырь приемлемым для применения при контрацепции у женщин при использовании пластыря один раз в неделю.
EA200601089A 2003-12-12 2004-12-10 Композиция для трансдермальной доставки гормонов без необходимости использования агентов, усиливающих проникновение, и ее применения EA011160B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (2)

Publication Number Publication Date
EA200601089A1 true EA200601089A1 (ru) 2006-12-29
EA011160B1 EA011160B1 (ru) 2009-02-27

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601089A EA011160B1 (ru) 2003-12-12 2004-12-10 Композиция для трансдермальной доставки гормонов без необходимости использования агентов, усиливающих проникновение, и ее применения

Country Status (15)

Country Link
JP (1) JP4965263B2 (ru)
KR (1) KR101168449B1 (ru)
CN (1) CN1913878B (ru)
AU (1) AU2004298930B2 (ru)
BR (1) BRPI0417530B8 (ru)
CA (1) CA2549916C (ru)
CU (1) CU23868B1 (ru)
EA (1) EA011160B1 (ru)
EC (1) ECSP066694A (ru)
IL (1) IL176112A (ru)
MX (1) MXPA06006682A (ru)
NO (1) NO341989B1 (ru)
NZ (1) NZ548091A (ru)
WO (1) WO2005058287A2 (ru)
ZA (1) ZA200605713B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE333271T1 (de) 2003-02-21 2006-08-15 Schering Ag Uv-stabiles transdermales pflaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
FR2900048B1 (fr) * 2006-04-21 2012-11-16 Oreal Compositions comprenant un derive diphenyl-methane hydroxyle
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
DK2613772T3 (en) 2010-09-06 2017-03-06 Bayer Ip Gmbh TRANSDERMAL LOW DOSAGE PATTERNS WITH HIGH PHARMACEUTICAL RELEASE
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
EP2806862A2 (en) * 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
US20180125860A1 (en) * 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004397A1 (de) * 1988-10-27 1990-05-03 Schering Aktiengesellschaft Berlin Und Bergkamen Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
WO1992007590A1 (en) * 1990-10-29 1992-05-14 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
AU692944B2 (en) * 1994-11-18 1998-06-18 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
ES2190472T5 (es) * 1995-06-07 2012-03-09 Ortho-Mcneil Pharmaceutical, Inc. Parche transdérmico para la administración de 17-deacetil norgestimato, en combinación con un estrógeno.
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP4167750B2 (ja) * 1997-04-16 2008-10-22 久光製薬株式会社 経皮吸収用基剤及び該基剤を含有する経皮吸収製剤
JP4399044B2 (ja) * 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
KR20010112479A (ko) * 1999-07-01 2001-12-20 나까도미 히로다카 경피흡수 첩부제
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use

Also Published As

Publication number Publication date
BRPI0417530B1 (pt) 2018-01-23
NO341989B1 (no) 2018-03-12
CA2549916A1 (en) 2005-06-30
AU2004298930B2 (en) 2009-11-26
IL176112A0 (en) 2006-10-05
IL176112A (en) 2011-02-28
CU23868B1 (es) 2013-03-27
CU20100143A7 (es) 2011-10-31
CN1913878B (zh) 2010-05-26
MXPA06006682A (es) 2006-08-11
CN1913878A (zh) 2007-02-14
ECSP066694A (es) 2006-10-31
NO20062594L (no) 2006-07-10
JP4965263B2 (ja) 2012-07-04
WO2005058287A3 (en) 2006-03-02
WO2005058287A2 (en) 2005-06-30
ZA200605713B (en) 2008-01-08
CA2549916C (en) 2013-09-17
AU2004298930A1 (en) 2005-06-30
BRPI0417530A (pt) 2007-03-13
KR20060128910A (ko) 2006-12-14
JP2007513938A (ja) 2007-05-31
NZ548091A (en) 2009-12-24
KR101168449B1 (ko) 2012-07-25
BRPI0417530B8 (pt) 2021-05-25
EA011160B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
MY152750A (en) Transdermal delivery system of hormones without penetration enhancers
Abrams et al. Pharmacokinetic overview of Ortho Evra™/Evra™
DK0836506T4 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
ITMI961152A1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
DK0462189T3 (da) Kombinationsterapi til behandling af østrogenfølsomme sygdomme
MXPA04005211A (es) Sistemas terapeuticos transdermicos que contienen hormona esteroides y monocaprilato de propilenglicol.
SI1526856T1 (sl) Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
AR036970A1 (es) Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion
ATE253910T1 (de) Transdermale verabreichung von lasofoxifen
BR0013711A (pt) Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos
BR0314959A (pt) Emplastro transdérmico de 17beta-estradiol/levonorgestrel para terapia de reposição hormonal
SI20851B (sl) Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)
UY28668A1 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CN1997357A (zh) 透皮或透粘膜应用活性剂的用途和制剂
CU20060121A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
EA200100801A1 (ru) Применение половых гормонов при изготовлении фармацевтической композиции для назального введения, предназначенной для лечения нежелательного маточного кровотечения

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment